Inflammatory parameters in NSCLC with driver mutation

References

• Liu Q, Huang Q, Yu Z et al. Clinical characteristics of non-small-cell lung cancer patients with EGFR mutations and ALK & ROS1 fusions. Clin. Respir. J. 16(3), 216–225 (2022).
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim DW et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 371(23), 2167–2177 (2014).
   PubMed Web of Science ®Google Scholar
• Gao G, Ren S, Li A et al. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials. Int. J. Cancer 131(5), E822–E829 (2012).
   PubMed Web of Science ®Google Scholar
• Yang JC, Wu YL, Schuler M et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 16(2), 141–151 (2015).
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A et al. Cancer-related inflammation. Nature 454(7203), 436–444 (2008).
   PubMed Web of Science ®Google Scholar
• Sun K, Chen S, Xu J et al. The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis. J. Cancer Res. Clin. Oncol. 140(9), 1537–1549 (2014).
   PubMed Web of Science ®Google Scholar
• Yang R, Chang Q, Meng X et al. Prognostic value of systemic immune-inflammation index in cancer: a meta-analysis. J. Cancer 9(18), 3295–3302 (2018).
   PubMed Web of Science ®Google Scholar
• Yılmaz E, Ak R, Doğanay F. Usefulness of the neutrophil-to-lymphocyte ratio in predicting the severity of COVID-19 patients: a retrospective cohort study. São Paulo Med. J. 140, 81–86 (2021).
   Web of Science ®Google Scholar
• Guthrie GJ, Charles KA, Roxburgh CS et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit. Rev. Oncol. Hematol. 88, 218–230 (2013).
   PubMed Web of Science ®Google Scholar
• Dalkılınç Hökenek U, Kılıç M, Alışkan H. Investigation of the prognostic role of systemic immunoinflammatory index in patients with acute pancreatitis. Ulus Travma Acil. Cerrahi. Derg. 29(3), 316–320 (2023).
   PubMed Web of Science ®Google Scholar
• Liu X, Guan G, Cui X et al. Systemic immune-inflammation index (SII) can be an early indicator for predicting the severity of acute pancreatitis: a retrospective study. Int. J. Gen. Med. 14, 9483–9489 (2021).
   PubMed Web of Science ®Google Scholar
• Peng L, Wang Y, Liu F et al. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small-cell lung cancer treated with PD-1 inhibitors. Cancer Immunol. Immunother. 69(9), 1813–1822 (2020).
   PubMed Web of Science ®Google Scholar
• Bylicki O, Paleiron N, Margery J et al. Targeting the PD-1/PD-L1 immune checkpoint in EGFR-mutated or ALK-translocated non-small-cell lung cancer. Target. Oncol. 12(5), 563–569 (2017).
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373(2), 123–135 (2015).
   PubMed Web of Science ®Google Scholar
• Borghaei H, Brahmer J. Nivolumab in nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 374(5), 493–494 (2016).
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373(17), 1627–1639 (2015).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027), 1540–1550 (2016).
   PubMed Web of Science ®Google Scholar
• Naidoo J, Schindler K, Querfeld C et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol. Res. 4(5), 383–389 (2016).
   PubMed Web of Science ®Google Scholar
• Feng F, Zheng G, Wang Q et al. Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer. BMC Gastroenterol. 18(1), 148 (2018).
   PubMedGoogle Scholar
• Oh SY, Heo J, Noh OK et al. Absolute lymphocyte count in preoperative chemoradiotherapy for rectal cancer: changes over time and prognostic significance. Technol. Cancer Res. Treat. 17, 1533033818780065 (2018).
   Web of Science ®Google Scholar
• Dong ZY, Zhang JT, Liu SY et al. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small-cell lung cancer. Oncoimmunology 6(11), e1356145 (2017).
   PubMed Web of Science ®Google Scholar
• Reits EA, Hodge JW, Herberts CA et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Experim. Med. 203(5), 1259–1271 (2006).
   PubMed Web of Science ®Google Scholar
• Franceschini D, Franzese C, Navarria P et al. Radiotherapy and immunotherapy: can this combination change the prognosis of patients with melanoma brain metastases? Cancer Treat. Rev. 50, 1–8 (2016).
   PubMed Web of Science ®Google Scholar
• Soo RA, Lim SM, Syn NL et al. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small-cell lung cancer: current controversies and future directions. Lung Cancer 115, 12–20 (2018).
   PubMed Web of Science ®Google Scholar
• Schulkes KJG, Hamaker ME, Lammers JJ et al. Multidisciplinary decision-making regarding chemotherapy for lung cancer patients-An age-based comparison. Eur. J. Cancer Care 27, e12768 (2018).
   Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066), 255–265 (2017).
   PubMed Web of Science ®Google Scholar
• Gainor JF, Shaw AT, Sequist LV et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small-cell lung cancer: a retrospective analysis. Clin. Canc. Res. 22(18), 4585–4593 (2016).
   PubMed Web of Science ®Google Scholar
• Hegi ME, Rajakannu P, Weller M. Epidermal growth factor receptor: a re-emerging target in glioblastoma. Curr. Opin. Neurol. 25(6), 774–779 (2012).
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang S, Zhang B et al. Clinical management of non-small-cell lung cancer with concomitant EGFR mutations and ALK rearrangements: efficacy of EGFR tyrosine kinase inhibitors and crizotinib. Target. Oncol. 14(2), 169–178 (2019).
   PubMed Web of Science ®Google Scholar
• Guo D, Han A, Jing W et al. Preoperative to postoperative change in neutrophil-to-lymphocyte ratio predict survival in colorectal cancer patients. Fut. Oncol. 14(12), 1187–1196 (2018).
   PubMed Web of Science ®Google Scholar
• Hirahara N, Matsubara T, Mizota Y et al. Prognostic value of preoperative inflammatory response biomarkers in patients with esophageal cancer who undergo a curative thoracoscopic esophagectomy. BMC Surg. 16(1), 66 (2016).
   PubMedGoogle Scholar
• Ramagopalan S, Leahy TP, Ray J et al. The value of innovation: association between improvements in survival of advanced and metastatic non-small-cell lung cancer and targeted and immunotherapy. BMC Med. 19(1), 209 (2021).
   PubMed Web of Science ®Google Scholar
• Berardi R, Rinaldi S, Santoni M et al. Prognostic models to predict survival in patients with advanced non-small-cell lung cancer treated with first-line chemo- or targeted therapy. Oncotarget 7(18), 26916–26924 (2016).
   PubMedGoogle Scholar
• Zhang Y, Feng YC, Zhu HG et al. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant non-small-cell lung cancer patients treated with EGFR-TKIs. Medicine 97(30), e11648 (2018).
   PubMed Web of Science ®Google Scholar
• Ding PN, Roberts TL, Chua W et al. Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District. Intern. Med. J. 47(12), 1405–1411 (2017).
   PubMed Web of Science ®Google Scholar
• Hu Y, Shen J, Liu R et al. Prognostic value of pretreatment prognostic nutritional index in non-small-cell lung cancer: a systematic review and meta-analysis.Inter. J. Biolog. Mark. 33(4), 372–378 (2018).
   PubMed Web of Science ®Google Scholar
• Ju Q, Huang T, Zhang Y et al. Systemic immune-inflammation index predicts prognosis in patients with different EGFR-mutant lung adenocarcinoma. Medicine 100(6), e24640 (2021).
   PubMed Web of Science ®Google Scholar